<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>modification_summary_b_034.html</title>
</head>
<body>
<p>* The company has changed its name.</p>
<p>* The business focus now includes technology licensed from a third party.</p>
<p>* MuGard is now licensed in additional markets, including Europe and Australia.</p>
<p>* R&amp;D spending reflects a new increase in scientific consulting expenses.</p>
<p>* An increase in MuGard product returns is a newly disclosed factor.</p>
<p>* A large increase in stock compensation expense is now reported.</p>
<p>* Interest on unpaid dividends is a new reason for increased interest expense.</p>
<p>* All unpaid preferred stock dividends were converted into common stock.</p>
<p>* The derivative liability related to warrants was eliminated upon expiration.</p>
<p>* The company now funds operations through public, not just private, sales.</p>
<p>* A new underwritten public offering of stock and warrants was completed.</p>
<p>* The firm&#x27;s financial position shifted from a working capital deficit to a surplus.</p>
<p>* A significant new financing event occurred in December 2014.</p>
<p>* New short-term &quot;Grid Notes&quot; were disclosed as a financing instrument.</p>
<p>* The company acquired a new worldwide license for plasma-derived therapeutic biologics.</p>
<p>* A new license fee from Hanmi was identified as a source of funds.</p>
<p>* The operational funding forecast was extended into the second quarter of 2016.</p>
<p>* A new factor affecting capital needs is the success of newly licensed technologies.</p>
<p>* &quot;ProctiGard&quot; is newly mentioned as a research and development project.</p>
<p>* A new worldwide licensing agreement for therapeutic biologics was entered into.</p>
<p>* The accounting policy for product sales and allowances has been removed.</p>
<p>* Series A preferred stock was converted, eliminating the related derivative liability.</p>
<p>* License revenue recognition now includes the period of performance obligation.</p>
<p>* New disclosures detail the inputs for the stock compensation valuation model.</p>
</body>
</html>
